Focus Financial Network Inc. Buys Shares of 3,268 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Focus Financial Network Inc. purchased a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 3,268 shares of the medical equipment provider’s stock, valued at approximately $292,000.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Wilmington Savings Fund Society FSB bought a new position in Lantheus in the third quarter worth about $25,000. Signaturefd LLC raised its position in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 92 shares during the period. UMB Bank n.a. lifted its holdings in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 134 shares during the last quarter. RiverPark Advisors LLC acquired a new position in Lantheus during the 3rd quarter valued at approximately $74,000. Finally, CWM LLC grew its stake in Lantheus by 63.0% during the 3rd quarter. CWM LLC now owns 750 shares of the medical equipment provider’s stock worth $82,000 after buying an additional 290 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Price Performance

Lantheus stock opened at $79.94 on Friday. Lantheus Holdings, Inc. has a 12-month low of $56.06 and a 12-month high of $126.89. The stock has a market capitalization of $5.56 billion, a PE ratio of 13.30 and a beta of 0.44. The firm has a 50 day simple moving average of $91.43 and a 200-day simple moving average of $97.79.

Analyst Ratings Changes

LNTH has been the topic of a number of recent research reports. The Goldman Sachs Group started coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price on the stock. JMP Securities reiterated a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, Truist Financial reiterated a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.